Investors
Antibody discovery and development for clinical application
$5bn+
Third party antibody development for clinical application
~5-8%+
Long-term annual trend growth
Beyond their use as research tools, over the last two decades, antibodies have become a critical component of many diagnostic assays. These assays have the potential to measure key biomarkers and provide clinicians with crucial insight to aid an effective diagnosis. Furthermore, using IVD assays as a companion diagnostic helps to screen patients and ensure that prescribed therapeutic agents will be efficacious for the specific disease variant. This can provide better clinical outcomes for the patient as well a more effective use of healthcare resources. As such IVD assays are an increasingly important part of clinical disease diagnosis, management and treatment selection. This is driving a rapid expansion of the companion diagnostics market, which is expected to reach $6 billion by 2025, according to industry data.
In addition, antibodies themselves are increasingly being used as therapeutics for a wide range of diseases. For example, monoclonal antibody therapies have various advantages compared to traditional chemo and radio therapies, such as fewer treatment-related adverse effects and high target specificity. As a result, biological drugs increasingly represent a larger proportion of drugs in the global research and development pipeline. This trend is expected to continue.
Worldwide total pharmaceutical R&D spend in 2012-2026
Source: EvaluatePharma, June 2020
We serve this market by leveraging the expertise and content from our proteomic research reagent business as well as our innovation capabilities to provide high-quality reagents to clinical and instrument platform partners. This is realized both through the provision of our in-house catalogue products, which we are able to out license to clinical partners, as well as the custom development of novel products for potential use in these markets. We believe customers are choosing to partner with us as a result of our unique antibody discovery and innovation capabilities, strong IP protection, precise and reliable reagents and our ability to support their needs as they progress through regulatory approvals.
Biological drugs as % of global drugs pipeline
Source: Pharmaprojects, January 2019
We believe the macro environment and dynamics within the diagnostic and biological therapeutics markets are attractive and expect this market to grow at a long-term growth rate of approximately 4% to 8% per annum, driven primarily by:
- biopharmaceutical research and development spending;
- increasing demand for accurate diagnoses to support high-cost therapeutic prescription;
- the move from small to large molecule biologics;
- the rise of precision medicine; and
- the trend toward industry outsourcing.
Rise of immuno-oncology as a therapeutics strategy for cancer
Source: Pharmaprojects, January 2019
Proteomic research reagents
Learn more about the drivers of the proteomic research reagents market
Market overview
Learn more about the markets we serve
Registered Office:
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
VIEW PRODUCTS
© Abcam Limited. all rights reserved.
Abcam Limited is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
